NASDAQ:BIOL BIOLASE - BIOL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.56 +0.02 (+4.05%) (As of 02/2/2023 09:11 AM ET) Add Compare Share Share Today's Range$0.56▼$0.5650-Day Range$0.38▼$1.0252-Week Range$0.37▼$10.70Volume11,052 shsAverage Volume1.08 million shsMarket Capitalization$4.34 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BIOLASE MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,658.9% Upside$9.50 Price TargetShort InterestHealthy12.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 3 Articles This WeekInsider TradingSelling Shares$2,653 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, BIOLASE has a forecasted upside of 1,658.9% from its current price of $0.54.Amount of Analyst CoverageBIOLASE has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted12.75% of the float of BIOLASE has been sold short.Short Interest Ratio / Days to CoverBIOLASE has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BIOLASE has recently decreased by 36.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOL. Previous Next 2.8 News and Social Media Coverage News SentimentBIOLASE has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BIOLASE this week, compared to 1 article on an average week.Search Interest9 people have searched for BIOL on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows16 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is an increase of 433% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,653.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of BIOLASE is held by insiders.Percentage Held by InstitutionsOnly 20.68% of the stock of BIOLASE is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBIOLASE has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BIOLASE (NASDAQ:BIOL) StockBIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.Read More Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOL Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)January 25, 2023 | finance.yahoo.comBIOLASE REJECTS SONENDO'S "PATENTLY ABSURD" CLAIMSFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 23, 2023 | marketwatch.comMedical Lasers Market (New Research Insights) Dominated Regions 2023: Upcoming Demand, Global Size and Share Forecast to 2027January 23, 2023 | americanbankingnews.comBIOLASE's (BIOL) "Buy" Rating Reiterated at Lake Street CapitalJanuary 18, 2023 | finance.yahoo.comBIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023January 12, 2023 | finance.yahoo.comBIOLASE RECEIVES TOP WORKPLACES 2022 AWARDJanuary 10, 2023 | finance.yahoo.comBIOLASE INC. ANNOUNCES PRICING OF APPROXIMATELY $9.75 MILLION UNDERWRITTEN PUBLIC OFFERINGFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 29, 2022 | marketwatch.comThe Dental Diode Lasers market research report's industry experts have examined the profitability and growth possibilities.December 28, 2022 | marketwatch.comWith 2.7% CAGR, Dental Equipment Market 2023 To Garner Overwhelming Hike In Revenues by 2028 | 106 Pages ReportDecember 18, 2022 | marketwatch.comDental Tourism Market is booming in near Future 2023-2028November 14, 2022 | finance.yahoo.comBIOLASE to Participate in the Benchmark Discovery One-on-One Investor Conference on December 1, 2022 in New YorkNovember 10, 2022 | finance.yahoo.comBIOLASE DELIVERS 26% REVENUE GROWTH YEAR OVER YEAR IN THIRD QUARTER AND RAISES 2022 FULL YEAR REVENUE GUIDANCEOctober 27, 2022 | finance.yahoo.comBIOLASE, Inc to Report Third Quarter 2022 Results on November 10, 2022October 18, 2022 | benzinga.comOutlook on the Cosmetic Dentistry Global Market to 2030 - Featuring 3M, Sirona Dental Systems, A-Dec and - BenzingaOctober 13, 2022 | finance.yahoo.comBIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICEROctober 6, 2022 | globenewswire.comRising Concerns about the Dental Hygiene Due to the Changing Lifestyle is Uplifting the Periodontal Market: Future Market Insights, Inc. - GlobeNewswireOctober 6, 2022 | benzinga.comGlobal Cosmetic Dentistry Market Report (2022 to 2030) - Increasing Consumer Awareness and Rising Focus o - BenzingaOctober 5, 2022 | finance.yahoo.comBIOLASE LAUNCHES RESEARCH GRANT PORTAL TO ACCELERATE CLINICAL STUDIES ON INNOVATIVE DENTAL LASER TECHNOLOGYOctober 1, 2022 | money.usnews.comBiolase IncSeptember 30, 2022 | globenewswire.comDental Laser Market to Hit Sales of $337.08 Million By 2028 | US is the Largest Export of Dental Lasers | SkyQuest Technology - GlobeNewswireSeptember 22, 2022 | finance.yahoo.comBIOLASE DOCUSERIES, "TALK DENTAL TO ME" TO BE PRODUCED BY PROVIDENCE FILM GROUPSeptember 7, 2022 | msn.comBiolase Earnings Perspective: Return On Capital EmployedSeptember 6, 2022 | benzinga.com(BIOL) – Biolase Earnings Perspective: Return On Capital Employed - BenzingaAugust 31, 2022 | finance.yahoo.comWorldwide Dental Equipment Industry to 2027 - Rising Geriatric Population is Driving Growth - Yahoo FinanceAugust 31, 2022 | finance.yahoo.comBIOLASE ANNOUNCES DEVELOPMENT OF STRATEGIC PLAN TO PARTNER WITH POSTGRADUATE DENTAL SPECIALTY PROGRAMS ACROSS THE U.S.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOL Company Calendar Last Earnings11/10/2022Today2/02/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees158Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$14.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,590.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,160,000.00 Net Margins-51.38% Pretax Margin-51.17% Return on Equity-118.42% Return on Assets-48.29% Debt Debt-to-Equity Ratio0.92 Current Ratio2.46 Quick Ratio1.27 Sales & Book Value Annual Sales$39.19 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$4.11 per share Price / Book0.14Miscellaneous Outstanding Shares7,720,000Free Float7,559,000Market Cap$4.34 million OptionableNot Optionable Beta1.38 Key ExecutivesJohn R. BeaverPresident, Chief Executive Officer & DirectorSteven SandorChief Operating OfficerJennifer BrightonChief Financial OfficerRussell MorrowChief Dental OfficerWilliam E. BrownVice President-Innovation & Business DevelopmentKey CompetitorsContraFectNASDAQ:CFRXAdvaxisNASDAQ:ADXSKiora PharmaceuticalsNASDAQ:KPRXHistogenNASDAQ:HSTOAmpio PharmaceuticalsNYSE:AMPEView All CompetitorsInsiders & InstitutionsPerkins Capital Management Inc.Sold 85,874 shares on 1/26/2023Ownership: 0.598%Jonathan T Md LordSold 3,537 sharesTotal: $2,652.75 ($0.75/share)Essex Investment Management Co. LLCBought 40,440 shares on 11/15/2022Ownership: 1.473%Citadel Advisors LLCSold 8,268 shares on 11/15/2022Ownership: 0.245%Armistice Capital LLCBought 52,887 shares on 11/14/2022Ownership: 10.197%View All Insider TransactionsView All Institutional Transactions BIOL Stock - Frequently Asked Questions Should I buy or sell BIOLASE stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares. View BIOL analyst ratings or view top-rated stocks. What is BIOLASE's stock price forecast for 2023? 3 analysts have issued 12-month price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $5.00 to $14.00. On average, they expect the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 1,658.9% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts. How have BIOL shares performed in 2023? BIOLASE's stock was trading at $0.65 at the beginning of the year. Since then, BIOL stock has decreased by 16.9% and is now trading at $0.5401. View the best growth stocks for 2023 here. When is BIOLASE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our BIOL earnings forecast. How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) released its earnings results on Thursday, November, 10th. The medical technology company reported ($1.10) earnings per share for the quarter. The medical technology company had revenue of $12.01 million for the quarter. BIOLASE had a negative net margin of 51.38% and a negative trailing twelve-month return on equity of 118.42%. When did BIOLASE's stock split? BIOLASE shares reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What guidance has BIOLASE issued on next quarter's earnings? BIOLASE updated its fourth quarter 2022 earnings guidance on Sunday, January, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.00 million-$14.40 million, compared to the consensus revenue estimate of $13.18 million. What is John R. Beaver's approval rating as BIOLASE's CEO? 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS). What is BIOLASE's stock symbol? BIOLASE trades on the NASDAQ under the ticker symbol "BIOL." Who are BIOLASE's major shareholders? BIOLASE's stock is owned by a number of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (0.60%). Insiders that own company stock include Jack W Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg. View institutional ownership trends. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BIOLASE's stock price today? One share of BIOL stock can currently be purchased for approximately $0.54. How much money does BIOLASE make? BIOLASE (NASDAQ:BIOL) has a market capitalization of $4.17 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. How many employees does BIOLASE have? The company employs 158 workers across the globe. How can I contact BIOLASE? BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677. This page (NASDAQ:BIOL) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.